- call +1-201-465-4211
- email sales@mrinsights.biz
Cancer immunotherapy is a type of cancer treatment that boosts the human bodys natural immune system to fight against the cancer cells. This therapy is provided to cancer patients to stop the spread of cancer, to slow down the growth of cancer cells, and to improve the natural immunity for destroying the cancer cells.
Scope of the Report:
This report studies the Cancer Immunotherapies market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Cancer Immunotherapies market by product type and applications/end industries.
Rising R&D in cancer immunotherapy is resulting in introduction of advanced treatment options that are more effective and efficient. A paradigm shift from traditional chemotherapies to immunotherapies is propelling the overall market.
The world cancer immunotherapy market is foretold to gain impetus due to rising popularity of patient assistance programs and broad portfolio of promising pipeline drugs. However, there could be more significant factors augmenting the demand in the market. For instance, rise in requirement of cancer monoclonal antibodies and launch of more effective bioinformatics tools offering improved drug development options could help with more demand for cancer immunotherapy. Furthermore, surge in adoption of immunotherapy therapeutics compared to conventional ones and high incidence of cancer could help the market to increase growth in the coming years.
The Americas accounted for approximately 47% of the market share of the global cancer immunotherapies market in 2015. High incidences of cancer in regions like the US, Canada, and Latin America are expected to contribute to the market growth in this region. region. This has led to an increase in consumption of immunotherapies that is used to treat cancer patients, thereby aiding the market growth.
The global Cancer Immunotherapies market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Cancer Immunotherapies.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Amgen
Bristol Mayer’s Squibb
F. Hoffmann-La Roche
Merck
Takeda
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Monoclonal Antibodies
Cancer Vaccines
Check Point Inhibitors
Immunomodulators
Market Segment by Applications, can be divided into
Lung
Breast
Colorectal
Melanoma
Prostate
Head & Neck
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Cancer Immunotherapies Market Overview
1.1 Product Overview and Scope of Cancer Immunotherapies
1.2 Classification of Cancer Immunotherapies by Types
1.2.1 Global Cancer Immunotherapies Revenue Comparison by Types (2017-2023)
1.2.2 Global Cancer Immunotherapies Revenue Market Share by Types in 2017
1.2.3 Monoclonal Antibodies
1.2.4 Cancer Vaccines
1.2.5 Check Point Inhibitors
1.2.6 Immunomodulators
1.3 Global Cancer Immunotherapies Market by Application
1.3.1 Global Cancer Immunotherapies Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Lung
1.3.3 Breast
1.3.4 Colorectal
1.3.5 Melanoma
1.3.6 Prostate
1.3.7 Head & Neck
1.4 Global Cancer Immunotherapies Market by Regions
1.4.1 Global Cancer Immunotherapies Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Cancer Immunotherapies Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Cancer Immunotherapies Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Cancer Immunotherapies Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Cancer Immunotherapies Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Cancer Immunotherapies Status and Prospect (2013-2023)
1.5 Global Market Size of Cancer Immunotherapies (2013-2023)
2 Manufacturers Profiles
2.1 Amgen
2.1.1 Business Overview
2.1.2 Cancer Immunotherapies Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Amgen Cancer Immunotherapies Revenue, Gross Margin and Market Share (2016-2017)
2.2 Bristol Mayer’s Squibb
2.2.1 Business Overview
2.2.2 Cancer Immunotherapies Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Bristol Mayer’s Squibb Cancer Immunotherapies Revenue, Gross Margin and Market Share (2016-2017)
2.3 F. Hoffmann-La Roche
2.3.1 Business Overview
2.3.2 Cancer Immunotherapies Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 F. Hoffmann-La Roche Cancer Immunotherapies Revenue, Gross Margin and Market Share (2016-2017)
2.4 Merck
2.4.1 Business Overview
2.4.2 Cancer Immunotherapies Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Merck Cancer Immunotherapies Revenue, Gross Margin and Market Share (2016-2017)
2.5 Takeda
2.5.1 Business Overview
2.5.2 Cancer Immunotherapies Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Takeda Cancer Immunotherapies Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cancer Immunotherapies Market Competition, by Players
3.1 Global Cancer Immunotherapies Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Cancer Immunotherapies Players Market Share
3.2.2 Top 10 Cancer Immunotherapies Players Market Share
3.3 Market Competition Trend
4 Global Cancer Immunotherapies Market Size by Regions
4.1 Global Cancer Immunotherapies Revenue and Market Share by Regions
4.2 North America Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
4.3 Europe Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
4.5 South America Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
5 North America Cancer Immunotherapies Revenue by Countries
5.1 North America Cancer Immunotherapies Revenue by Countries (2013-2018)
5.2 USA Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
5.3 Canada Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
5.4 Mexico Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
6 Europe Cancer Immunotherapies Revenue by Countries
6.1 Europe Cancer Immunotherapies Revenue by Countries (2013-2018)
6.2 Germany Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
6.3 UK Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
6.4 France Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
6.5 Russia Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
6.6 Italy Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Cancer Immunotherapies Revenue by Countries
7.1 Asia-Pacific Cancer Immunotherapies Revenue by Countries (2013-2018)
7.2 China Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
7.3 Japan Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
7.4 Korea Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
7.5 India Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
8 South America Cancer Immunotherapies Revenue by Countries
8.1 South America Cancer Immunotherapies Revenue by Countries (2013-2018)
8.2 Brazil Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
8.3 Argentina Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
8.4 Colombia Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Cancer Immunotherapies by Countries
9.1 Middle East and Africa Cancer Immunotherapies Revenue by Countries (2013-2018)
9.2 Saudi Arabia Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
9.3 UAE Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
9.4 Egypt Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
9.5 Nigeria Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
9.6 South Africa Cancer Immunotherapies Revenue and Growth Rate (2013-2018)
10 Global Cancer Immunotherapies Market Segment by Type
10.1 Global Cancer Immunotherapies Revenue and Market Share by Type (2013-2018)
10.2 Global Cancer Immunotherapies Market Forecast by Type (2018-2023)
10.3 Monoclonal Antibodies Revenue Growth Rate (2013-2023)
10.4 Cancer Vaccines Revenue Growth Rate (2013-2023)
10.5 Check Point Inhibitors Revenue Growth Rate (2013-2023)
10.6 Immunomodulators Revenue Growth Rate (2013-2023)
11 Global Cancer Immunotherapies Market Segment by Application
11.1 Global Cancer Immunotherapies Revenue Market Share by Application (2013-2018)
11.2 Cancer Immunotherapies Market Forecast by Application (2018-2023)
11.3 Lung Revenue Growth (2013-2018)
11.4 Breast Revenue Growth (2013-2018)
11.5 Colorectal Revenue Growth (2013-2018)
11.6 Melanoma Revenue Growth (2013-2018)
11.7 Prostate Revenue Growth (2013-2018)
11.8 Head & Neck Revenue Growth (2013-2018)
12 Global Cancer Immunotherapies Market Size Forecast (2018-2023)
12.1 Global Cancer Immunotherapies Market Size Forecast (2018-2023)
12.2 Global Cancer Immunotherapies Market Forecast by Regions (2018-2023)
12.3 North America Cancer Immunotherapies Revenue Market Forecast (2018-2023)
12.4 Europe Cancer Immunotherapies Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Cancer Immunotherapies Revenue Market Forecast (2018-2023)
12.6 South America Cancer Immunotherapies Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Cancer Immunotherapies Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Cancer Immunotherapies Picture
Table Product Specifications of Cancer Immunotherapies
Table Global Cancer Immunotherapies and Revenue (Million USD) Market Split by P
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
